Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-90
¥100 million (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending March 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales1,263 Hundreds of millions of yen-2.9%
Operating profit36 Hundreds of millions of yen-71.6%
Ordinary income40 Hundreds of millions of yen-69.5%
Net income34 Hundreds of millions of yen-62.0%
Selling, general and administrative expenses481 Hundreds of millions of yen
Operating profit margin2.9%, down 6.9 percentage points year on year
Full-year earnings forecast
Net Sales
1,218 Hundreds of millions of yen
Operating profit
20 Hundreds of millions of yen
Ordinary income
23 Hundreds of millions of yen
Net income
15 Hundreds of millions of yen
Research and development costs
93 Hundreds of millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
FY2026 actual-to-forecast achievement rate
Net Sales99.4%
Operating profit58.5%
Ordinary income64.0%
Net income71.8%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Plan not achievedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Decrease in gross profit-79 Hundreds of millions of yen
- Increase in R&D expenses-16 Hundreds of millions of yen
- Decrease in SG&A expenses excluding R&D expenses5 Hundreds of millions of yen
Key KPIsA metric the company considers important as a management benchmark.
- Beova share (own sales)30 %
- Lasvic share10.1 %
- Desalex share11.4 %
- Flutiform share19 %
- Estimated patient population9 Graph figures presented in units of ¥100 million
- Authorized-generic share among generics50% or higher
Unit price and quantity metricsThese figures show sales broken down by price and volume.
For generic pharmaceuticals, the company explains that volumes are growing, but the metric breaking down price and volume quantitatively is Not disclosedMarket Size / Share
- Overactive bladder (OAB) treatment market976 Hundreds of millions of yen
- Oral antibacterial market704 Hundreds of millions of yen
- Antihistamine market1,053 Hundreds of millions of yen
- ICS/LABA combination drug market756 Hundreds of millions of yen
- Beova share (own sales)30 %
- Lasvic share10.1 %
- Desalex share11.4 %
- Flutiform share19 %
Gross profit
¥51.6 billion, down 13.3% year on year| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | 1,263 Hundreds of millions of yen (YoY -2.9%) |
| Operating profit | 36 Hundreds of millions of yen (YoY -71.6%) |
| Ordinary income | 40 Hundreds of millions of yen (YoY -69.5%) |
| Net income | 34 Hundreds of millions of yen (YoY -62.0%) |
| Gross profit | ¥51.6 billion, down 13.3% year on year |
| Operating profit margin | 2.9%, down 6.9 percentage points year on year |
| Selling, general and administrative expenses | 481 Hundreds of millions of yen |
| Full-year earnings forecast | Net Sales 1,218 Hundreds of millions of yen / Operating profit 20 Hundreds of millions of yen / Ordinary income 23 Hundreds of millions of yen / Net income 15 Hundreds of millions of yen / Research and development costs 93 Hundreds of millions of yen |
| Progress against full-year forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / FY2026 actual-to-forecast achievement rate Net Sales 99.4% / Operating profit 58.5% / Ordinary income 64.0% / Net income 71.8% |
| Self-assessment against the plan | Plan not achieved |
| Breakdown of Factors Affecting the Change | Factors Decrease in gross profit / Amount -79 Hundreds of millions of yen, Factors Increase in R&D expenses / Amount -16 Hundreds of millions of yen, Factors Decrease in SG&A expenses excluding R&D expenses / Amount 5 Hundreds of millions of yen |
| Key KPIs | Indicator name Beova share (own sales) / Value 30 % / Year on year against the same period last year Not disclosed, Indicator name Lasvic share / Value 10.1 % / Year on year against the same period last year Not disclosed, Indicator name Desalex share / Value 11.4 % / Year on year against the same period last year Not disclosed, Indicator name Flutiform share / Value 19 % / Year on year against the same period last year Not disclosed, Indicator name Estimated patient population / Value 9 Graph figures presented in units of ¥100 million / Year on year against the same period last year Not disclosed, Indicator name Authorized-generic share among generics / Value 50% or higher / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | For generic pharmaceuticals, the company explains that volumes are growing, but the metric breaking down price and volume quantitatively is Not disclosed |
| Market Size / Share | Market Overactive bladder (OAB) treatment market / Value 976 Hundreds of millions of yen, Market Oral antibacterial market / Value 704 Hundreds of millions of yen, Market Antihistamine market / Value 1,053 Hundreds of millions of yen, Market ICS/LABA combination drug market / Value 756 Hundreds of millions of yen, Market Beova share (own sales) / Value 30 %, Market Lasvic share / Value 10.1 %, Market Desalex share / Value 11.4 %, Market Flutiform share / Value 19 % |
Items this document does not state (15)
Results for the three months of the current quarterSegment resultsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, operating profit declined primarily because gross profit decreased by ¥7.9 billion and R&D expenses increased by ¥1.6 billion. Revenue declined mainly because of lower sales of new pharmaceuticals and other products overseas. For the fiscal year ending March 2027, the company expects operating profit to decline as gross profit decreases due to the NHI drug price revision and lower sales of Desalex, while R&D expenses are expected to decrease because of lower upfront contract payment expenses following the prior year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.